^
Association details:
| Biomarker: | Chr del(3)(p12) |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Excerpt:
Common eliminated regions on 3p include 3p22 (AP20), 3p21 (CER1, CER2 and LUCA), 3p12 (ROBO1) and 3p14 (FHIT). When examining patients with copy number losses at these 4 regions in our cohort, we observed a significant reduction of survival in these patients compared with wild-type patients (mPFS, 61.5 vs. 65 days; survival rates at day 180, 0% vs. 31%, log rank P = 0.012, HR, 2.08; 95% CI, 1.09–4.00; Fig. 5A)...
DOI:
10.1158/1078-0432.CCR-19-0585
